FDA RMAT boosts inhaled gene therapy KB707, delivering IL‑2/IL‑12 to lung tumors; early trial shows responses with manageable ...

The FDA has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneous, chemo-free treatment for patients with EGFR-mutated non-small cell lung cancer across all ...

Researchers have shown that the IGFBP3 protein plays a relevant role in human lung development. The results of the study, which used organoids derived from embryonic lungs, open up new perspectives on ...

A team of scientists have developed a simple method for automated manufacturing of lung organoids which could revolutionize the development of treatments for lung disease. These organoids, miniature ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. On the regional level, as the Human Development Index ...

The 'cell of origin' of the second most common lung cancer and the way that it becomes dominant in the lung have been discovered, in a new study in mice and humans from researchers at UCL, the ...

Lung cancer remains the leading cause of cancer-related deaths worldwide, frequently presenting at a late, incurable stage. LUSC is the second most common subtype of lung cancer and develops when ...

Dec 3 (Reuters) - Roivant (ROIV.O), opens new tab will discontinue the development of its drug for a rare lung disease after it failed to show treatment benefits in patients in a mid-stage trial.

Mold is a silent threat, often going unnoticed as it quietly harms health. What's concerning is that exposure to mold during ...